SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Fløisand Y.)
 

Search: WFRF:(Fløisand Y.) > The CD34+ Cell Dose...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003578naa a2200613 4500
001oai:DiVA.org:uu-431527
003SwePub
008210114s2020 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:234595446
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4315272 URI
0247 a https://doi.org/10.2991/chi.d.200221.0012 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:2345954462 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Remberger, Matsu Uppsala universitet,Hematologi,Oslo University Hospital4 aut0 (Swepub:uu)matre804
2451 0a The CD34+ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors
264 c 2020
264 1b Springer Science and Business Media LLC,c 2020
338 a electronic2 rdacarrier
520 a The effect of CD34+ cell dose in allogeneic hematopoietic stem cell transplantation (HSCT) on overall survival (OS) and incidence of acute and chronic graft-versus-host disease (GvHD) has not been established and few studies have been performed. Our single center analysis included 189 patients with hematological malignancies who received peripheral blood stem cell (PBSC) grafts from sibling donors. Myeloablative conditioning was used in 88 cases and 101 received reduced intensity conditioning. The median CD34+ cell dose was 5.6 × 106/kg (0.6–17.0). In the multivariate analysis, a CD34 cell dose of 6–7 × 106/kg was associated with better OS and lower transplant-related mortality (TRM), while a dose of <5 × 106/kg led to increased relapse and reduced chronic GVHD (cGVHD). A high CD34 cell-dose (>6.5 × 106/kg) correlated with less acute GVHD (aGVHD) II–IV. We conclude that the CD34 cell dose has an impact on the outcome of HSCT from sibling donor PBSCs.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
653 a Cell dose
653 a CD34
653 a HSCT
653 a GVHD
653 a PBSC
653 a Klinisk immunologi
653 a Clinical Immunology
7001 a Grønvold, B.4 aut
7001 a Ali, M.4 aut
7001 a Mattsson, J.u Karolinska Institutet4 aut
7001 a Egeland, T.4 aut
7001 a Lundin, K. U.4 aut
7001 a Myhre, A.4 aut
7001 a Abrahamsen, I.4 aut
7001 a Heldal, D.4 aut
7001 a Dybedal, I.4 aut
7001 a Tjønnfjord, G. E.4 aut
7001 a Gedde-Dahl, T.4 aut
7001 a Fløisand, Y.4 aut
7102 a Uppsala universitetb Hematologi4 org
7730 t Clinical Hematology Internationald : Springer Science and Business Media LLCg 2:2, s. 74-81q 2:2<74-81x 2590-0048
8564 u https://doi.org/10.2991/chi.d.200221.001y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1517864/FULLTEXT02.pdfx primaryx Raw objecty fulltext:print
8564 u https://www.atlantis-press.com/article/125935438.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-431527
8564 8u https://doi.org/10.2991/chi.d.200221.001
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:234595446

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view